What should I know about Shionogi?
Shionogi is a Japanese pharmaceutical company, founded in 1878 and headquartered in Osaka, that researches and sells medicines. According to a company news release, its research focuses on infectious diseases and on pain and central nervous system conditions, with further work in oncology, rare diseases and sleep apnea. It sells products in Japan and overseas, including through its US subsidiary, Shionogi Inc. Shionogi also earns royalties from HIV medicines sold by ViiV Healthcare.
What are Shionogi's main drugs?
Shionogi's best-known medicines include Fetroja (cefiderocol), an antibiotic for serious infections caused by certain Gram-negative bacteria, and Xocova (ensitrelvir), an oral antiviral approved in the US for preventing COVID-19 after exposure in people aged 12 and over. It also sells Radicava ORS (edaravone) for ALS, according to a September 2026 company release. Royalties from ViiV Healthcare's HIV products were a major driver of income in the April–June 2026 quarter.
What is Shionogi currently developing?
Shionogi's pipeline is concentrated on infectious diseases. Its September 2026 IDWeek release mentions investigational agents aimed at antimicrobial resistance, COVID-19, influenza, rare fungal diseases and respiratory syncytial virus. It also describes xeruborbactam, a preclinical beta-lactamase inhibitor discovered by Qpex Biopharma, a Shionogi Group company. A supplemental US application for paediatric use of Fetroja has been accepted by the FDA. The company is also working in rare diseases and other areas of high medical need.
Is Shionogi publicly traded, and how big is it?
Yes. Shionogi is listed on the Tokyo Stock Exchange under the code 4507. One tracker put its market capitalisation at about $14.75 billion in October 2026, though the exact date was not given. For the April–June 2026 quarter, revenue was ¥163.3 billion, up 63.7% on the year, according to a results summary. The company forecast full-year revenue of ¥700 billion for the year to March 2027.